A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation

Meifang Li1†, Jilong Yang1†, Lenghe Zhang1†, Sanfang Tu1, Xuan Zhou1, Ze Tan2, Weijun Zhou1*, Yanjie He1* and Yuhua Li1*

Abstract

Background: Epidermal growth factor receptor (EGFR) and epidermal growth factor receptor pathway substrate 8 (Eps8) have been widely reported to be expressed in various tumors. Eps8 is an important active kinase substrate of EGFR that directly binds to the juxtamembrane (JXM) domain of EGFR to form an EGFR/Eps8 complex. The EGFR/Eps8 complex is involved in regulating cancer progression and might be an ideal target for antitumor therapy. This study focused on the screening of small-molecule inhibitors that target the EGFR/Eps8 complex in breast cancer and non-small cell lung cancer (NSCLC).

Methods: In silico virtual screening was used to identify small-molecule EGFR/Eps8 complex inhibitors. These compounds were screened for the inhibition of A549 and BT549 cell viability. The direct interaction between EGFR and Eps8 was measured using coimmunoprecipitation (CoIP) and JXM domain replacement assays. The antitumor effects of the inhibitors were analyzed in cancer cells and xenograft models. An acute toxicity study of EE02 was performed in a mouse model. In addition, the effect of the EE02 inhibitor on the protein expression of elements downstream of the EGFR/Eps8 complex was determined by western blotting and protein chip assays.

Results: In this study of nearly 390,000 compounds screened by virtual database screening, the top 29 compounds were identified as candidate small-molecule EGFR/Eps8 complex inhibitors and evaluated by using cell-based assays. The compound EE02 was identified as the best match to our selection criteria. Further investigation demonstrated that EE02 directly bound to the JXM domain of EGFR and disrupted EGFR/Eps8 complex formation. EE02 selectively suppressed growth and induced apoptosis in EGFR-positive and Eps8-positive breast cancer and NSCLC cells. More importantly, the PI3K/Akt/mTOR and MAPK/Erk pathways downstream of the EGFR/Eps8 complex were suppressed by EE02. In addition, the suppressive effect of EE02 on tumor growth in vivo was comparable to that of erlotinib at the same dose.

Conclusions: We identified EE02 as an EGFR/Eps8 complex inhibitor that demonstrated promising antitumor effects in breast cancer and NSCLC. Our data suggest that the EGFR/Eps8 complex offers a novel cancer drug target.

Keywords: Epidermal growth factor receptor (EGFR), Epidermal growth factor receptor pathway substrate 8 (Eps8), Breast cancer, NSCLC, small-molecule inhibitor

* Correspondence: zhouchunjun-123@163.com; hyjgzh2006@163.com; llyuhua2011@163.com
† Meifang Li, Jilong Yang and Lenghe Zhang are co-first authors.
1Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253 Gongye Dadao Zhong, Guangzhou, Guangdong 510282, People’s Republic of China
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Cancer is hallmarked by the accumulation of genetic variations and the loss of normal cellular regulatory processes and is a main cause of death worldwide [1, 2]. Although chemotherapy is the cornerstone of systemic cancer therapy, it has a modest effect on overall survival [3]. Lung cancer is still the leading cause of cancer-related death worldwide, and breast cancer is the most common type of noncutaneous malignancy and the leading cause of cancer-related death in women worldwide [4–6]. Thus, there is a great need to develop novel therapeutic modalities to improve survival rates [7].

Epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1, is a member of the receptor tyrosine kinase (RTK) family of cell surface receptors [8]. EGFR regulates differentiation, apoptosis, cell cycle progression, development, and transcription [9–11]. EGFR hyperactivity, caused either by mutation or overexpression of the ligand or receptor, contributes to a variety of human cancers [12]. EGFR consists of an extracellular domain, a single hydrophobic transmembrane segment, an intracellular portion with a juxtamembrane (JXM) segment, a protein kinase domain, and a carboxyterminal tail [8].

Recent studies have shown that the presence of the JXM domain is necessary for the full catalytic activity of EGFR [13–15]. A study by Thiel and Carpenter showed that compared with the activity of constructs containing the full-length intracellular domain (ICD) containing the JXM domain, the activity of intracellular EGFR constructs lacking the JXM domain was reduced by approximately 95% [15]. In a later study in the Carpenter laboratory, scanning alanine mutagenesis experiments showed that ICDs constructed with mutations at 36 different residues in the JXM domain reduced EGFR activity by approximately 50% [15]. Two of the mutations (V665A and L680A) were able to significantly reduce the activity of full-length EGFR [15]. These results show that most of the amino acids (aa) within the JXM domain play important roles in supporting the activation of the kinase domain [13–17]. The JXM domain not only links the transmembrane region to the kinase domain but also contains the initial 13 amino acids involved in the EGFR dimerization process [18]. Studies have shown that the JXM domain plays an activating role in EGFR, and the deletion of half of the C-terminal amino acids (664–682) in the JXM domain will affect the formation of EGFR dimers, resulting in the loss of EGFR kinase activity [13]. JXM domain V665 M or L679F amino acid mutations can increase EGFR activity due to the formation of a more stable EGFR dimer [13]. According to Sinclair et al., the peptide E1 derived from the JXM domain can bind to the EGFR JXM domain and effectively reduce EGFR dimerization, which thereby affects EGFR activity and reduces cell viability [19]. Boran once demonstrated that the JXM domain of EGFR is essential to the activation of EGFR, and the JXM domain activates and regulates EGFR activation and is a potential target for the development of new EGFR inhibitors [14].

Epidermal growth factor receptor pathway substrate 8 (Eps8) is an important active kinase substrate of EGFR [2, 20]. Eps8 is efficiently phosphorylated by various tyrosine kinases, both receptor (RTK) and nonreceptor types, and is a typical signaling protein, with a molecular weight of 97 kDa and containing a phosphotyrosine binding protein (PTB) domain, an Src homology 3 (SH3) domain and a sterile alpha-pointed (SAM-PNT) domain [21, 22]. Eps8 is frequently overexpressed in breast, lung and other malignancies but rarely in normal tissues [23–26]. Further studies of Eps8 have revealed that a domain that encompasses amino acids 298 to 362 provides a binding surface for the JXM domain of EGFR [27]. Studies by Fazioli et al. and Castagnino et al. have shown that Eps8 directly binds to the JXM domain of EGFR and is phosphorylated, which activates a series of downstream signaling pathways [20, 27], and thus promotes tumor progression. Furthermore, the aberrant expression of Eps8 often suggests an unfavorable prognosis for cancer patients [20, 27, 28]. Therefore, Eps8 is considered a novel potential target for specific cancer therapy.

Eps8 directly binds to the JXM domain of EGFR and forms an EGFR/Eps8 complex. Studies on the EGFR/Eps8 complex in malignancies are limited. In the present study, we focused on the EGFR/Eps8 complex as a promising tumor target for cancer therapy. The Eps8-derived 9-amino acid peptide 327, which partly mimics the EGFR binding region of Eps8, functions as a protein-protein interaction module that can disrupt the EGFR/Eps8 complex, prevent the activity of the downstream EGFR pathway, and exert antitumor effects [2]. In our opinion, there is another approach to disrupt the EGFR/Eps8 complex. Direct inhibition of the EGFR/Eps8 complex by using drug-like, nonpeptide small molecules have several advantages, including blocking the activity mediated by EGFR/Eps8 complex activation, improved cell permeability and better in vivo stability and bioavailability. Based on the high-resolution X-ray 3D crystal structure of JXM and the kinase domain of EGFR, the JXM domain is critical for EGFR activation and acts as a binding site for Eps8 [13, 27]. Therefore, we hypothesize that a small molecule that binds to the JXM domain of EGFR may directly disrupt EGFR/Eps8 complex formation and block the downstream pathway of the complex. In this work, we report the discovery of an EGFR/Eps8 complex small-molecule inhibitor through virtual database screening.

Methods
Structure-based virtual screening
To identify potential candidate compounds that can disrupt EGFR/Eps8 complex formation, the crystal structure of EGFR solved at 2.8-Å resolution was retrieved from the
Protein Data Bank (PDB ID code 3GOP) (DOI: https://doi.org/10.2210/pdb3GOP/pdb) [29] and used in this study. The chemical databases used in our virtual screening were provided by TopScience Co., Ltd. Collectively, these databases offer a collection of 390,000 small-molecule organic compounds. The chemical catalogs provide only 2D chemical structures; the 3D structural models were generated by using SYBYL software (Version 7.3, Tripos Associates, St. Louis) with the standard settings. The molecular docking program SYBYL was used to perform the virtual screening. The binding cavity in the EGFR JXM domain was the region targeted for docking. SYBYL software was used to assign the standard AMBER (refers to a set of molecular mechanical force fields for the simulation of biomolecules) atomic partial charges on the EGFR protein and the Gasteiger-Hückel atomic partial charges on each ligand molecule to be docked. The parameters used for modeling docking, which controlled how the docking was performed in our work, were standard settings according to the guidelines of the software [30]. Each molecule in the assessed databases with a molecular weight between 200 and 1000 was docked into the targeted binding site of EGFR. The top 5% scored compounds from each database, as selected by SYBYL, were extracted and combined to provide a total of 18,000 candidate compounds. The preselected 18,000 compounds then were reranked according to their binding affinities as estimated by the total score. Of the best-scored 50 compounds selected by the total score from the 18,000 compounds, physical samples of 29 of these compounds were purchased from TopScience Co., Ltd. PyMOL software (Version 1.6.X, Open-Source) was obtained from the PyMOL website (https://pymol.org) [31].

Cell lines and culture conditions
The non-small cell lung cancer cell lines (A549, H460, H1975), breast cancer cell lines (MCF-7, BT549, MDA-MB-468) and multiple myeloma cell line (IM-9) were kept in our laboratory (Hematological Laboratory of Zhujiang Hospital, Guangzhou, China) and genotyped to verify their authenticity. Human normal lung epithelial cell line (BEAS-2B) and human normal mammary epithelial cell line (MCF-10A) were purchased from FuHeng Cell Center (Shanghai, china) and genotyped to verify their authenticity. Normal PBMCs were obtained from 5 unrelated healthy donors at Southern Medical University (Guangzhou, China). MCF-10A cell line was cultivated in MEpiCM medium (Cat No. 7611, ScienCell, San Diego, California, USA) and other cell lines were cultivated in DMEM or RPMI 1640 medium (Invitrogen, Grand Island, NY, USA) with 10% fetal bovine serum (FBS; Invitrogen) at 37°C with 5% CO2.

Compounds and growth-inhibiton assay
For testing different compounds, A549 and BT549 cells were plated in a 96-well-plate (5 × 10³ cells/well) and incubated for 24 h before treatment. Then cells were exposed to the compounds for 24 h at a final concentration of 10 μM. After treatment, 10 μl of CCK-8 reagent (Dojindo Laboratories, Japan) was added to each well, and cells were incubated for 3 h at 37°C and 5% CO2. The optical density (OD) was analyzed at 450 nm. The data obtained are presented as percentage viability in the graph.

Plasmid constructs and the creation of stable EGFR-overexpressing cell lines
The wild-type EGFR (wt-EGFR) sequence was obtained through an NCBI search, the whole length of the gene was synthesized by GENEWIZ, Inc. (Germantown, MD), and the two ends were cloned into the vector PCD513B (SBI) using the restriction site NheI/NotI. At the same time, 30 amino acids in the JXM domain (aa: 650–679) were replaced with a 10 GGS repeating sequence to obtain the new gene sequence mutant-type EGFR (mut-EGFR), which was produced by GENEWIZ, Inc. (Germantown, MD), and both ends were cloned into the vector PCD513B (SBI) by using the restriction site NheI/NotI [32]. The sequence integrity of the completed two vectors were ensured by sequencing. MCF-7 cells were transfected with wt-EGFR, mut-EGFR or PCD513B empty vector using Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocol. Twenty-four hours after transfection, the culture medium was replaced by medium supplemented with 1.0 μg/ml puromycin. Two or 3 days later, the cells that grew to approximately 90% confluency were passed and seeded at a high dilution ratio into 150-mm cell culture dishes. The medium containing puromycin was replaced every 2–3 days until colonies of cells appeared approximately 2 weeks after the initial seeding. Several colonies in each transfection group were selected for further experiments and designated as MCF-7-NC, MCF-7-wt-EGFR or MCF-7-mut-EGFR.

Creation and characterization of stable EGFR knockdown cell lines
EGFR expression was stably knocked down in A549, H460 and MDA-MB-468 cells via RNA interference (RNAi). The annealed oligonucleotide fragments encoding short hairpin transcripts corresponding to EGFR were as follows: CCGGGCAGATCATCAGAGGAAA-TATCTCGAGATATTTCCTCTGATGATCTGCTTTTT and CCGGGGAGATAAGTGATGGAGATGTCTCGAGATATTTCCTCTGATGATCTGCTTTTT. The nontargeting empty plasmid was used as the control shRNA plasmid. According to the manufacturer’s instructions, A549, H460 and MDA-MB-468 cells (2 × 10⁵ cells/well in six-well plates) were transfected separately with the control shRNA plasmid or the EGFR shRNA plasmid using Lipofectamine 2000 (Invitrogen). After 24 h, the culture
medium was replaced with medium supplemented with puromycin at a selection concentration. Several colonies in each transfection group were selected for further experiments and designated as A549-NC, A549-EGFR/shRNA1, A549-EGFR/shRNA2, H460-NC, H460-EGFR/shRNA1, H460-EGFR/shRNA2, MDA-MB-468-NC, MDA-MB-468-EGFR/shRNA1 or MDA-MB-468-EGFR/shRNA2.

**Cell proliferation/survival assays and apoptosis measurements**

To test the effects of EE02 on the biological activities of tumor cells and normal cells, tumor cell lines, normal cell lines and normal PBMCs were plated in a 96-well plate (5 x 10^3 cells/well) and incubated for 24 h before treatment. All cells were then incubated with different concentrations of EE02 (0, 1, 2.5, 5.0, 7.5 or 10 μM) for 24 h. CCK-8 (Dojindo Laboratories, Japan) assays were carried out according to the manufacturer’s instructions. Colony formation assays were also performed. Cells (A549 and H460 were 300 cells/well, BT549 and MCF-7 were 500 cells/well) were seeded into six-well plates and treated with different concentration’s EE02 or DMSO on the following day. After 2 weeks, the cells were fixed with 4% formaldehyde and washed with PBS when colonies were visible. Crystal violet was added to the plates to stain the colonies. The number of apoptotic cells was analyzed by flow cytometry (BD Biosciences, Rockford, IL, USA).

**Western blot analysis**

All prepared cells were homogenized in IP lysis (CO-IP kit, Thermo Scientific, Cat No. #26149), and debris was removed by centrifugation at 12,000 g for 10 min at 4 °C. The protein concentrations were determined using a Bradford method on day 14. The vital organs were removed, fixed, and all animals were observed every day for symptoms and mortality for two weeks. The vehicle control group was observed at the same time. All of the surviving animals were euthanized at the end of the study. The vital organs of both the mouse that died and those that were euthanized were individually observed for overt pathology by necropsy, and the 50% lethal dose (LD50) was calculated by the Bliss method on day 14. The vital organs were removed, fixed, and preserved for pathological examination, and the tissue samples were stained with hematoxylin and eosin (H&E). The histopathological changes were observed under a light microscope. The data on the number of animals, the survival ratio, and the mean survival time were analyzed using the Kaplan-Meier method. The differences between the groups were compared using the log-rank test. The p-values less than 0.05 were considered statistically significant.

**AKT-1 phosphorylation antibody array and CoIP**

We performed human AKT-1 phosphorylation antibody arrays, which included 18 different antibodies (RayBiotech, Inc., USA) [34, 35]. All the steps are carried out according to the manufacturer’s instructions. Briefly, MDA-MB-468 cells from different groups (EE02 10 μM and DMSO control) were lysed and the total proteins were purified using the Cell and Tissue Protein Extraction Reagent (Kangchen, China). The protein concentrations were tested using a Bradford protein assay kit (Beyotime, China, Cat No. #KGP902). A total of 380 μg protein extract was added into each well and incubated for 3 h at room temperature. Then, the antibody arrays membranes were washed and incubated with HRP-Anti-Rabbit IgG antibody at room temperature for 2 h, and the HRP signal was detected using ImageQuant LAS4000 Scanner (GE Healthcare Corporate, USA). For the immunoprecipitation (CoIP) of endogenous proteins, 10 μg of anti-EGFR (Cat No. #4267, CST) or IgG (Cat No. #2729, CST) antibody was added to AminoLink plus coupling resin (Thermo Fisher Scientific, Pierce CoIP kit, Cat No. #26149) for antibody immobilization at room temperature for 100 min. Cells were lysed in cell lysis buffer at 4 °C for 30 min [36]. A total of 1000 μg protein extract was added into each tube of control agarose resin and incubated for 1 h at 4 °C. Then, the protein was centrifuged from the control agarose tube, and the protein-containing liquid was added to the antibody incubation tube, and the mixture was incubated at room temperature for 2 h. Immunoprecipitants were separated by SDS-PAGE after washing with the same buffer and were analyzed by immunoblotting with an anti-Eps8 antibody [37].

**Chemicals**

Erlotinib was purchased from Selleckchem, dissolved in DMSO at a final concentration of 50 mg/ml and stored at −20 °C.

**Acute intraperitoneal toxicity**

Thirty-five male and thirty-five female specific pathogen-free (SPF) BALB/c mice were randomly assigned to seven groups: six treatment groups and one vehicle control group, with five male and five female mice per group. The vehicle control group received DMSO in a volume of 5 mL/kg body weight (b.w.) by intraperitoneal injection. EE02 was dissolved in DMSO and administered to the mice at doses of 75.00, 86.25, 99.19, 114.19, 131.75 or 151.51 mg/kg b.w., and all animals were observed every day for symptoms and mortality for two weeks. The vehicle control group was observed at the same time. All of the surviving animals were euthanized at the end of the study. The vital organs of both the mouse that died and those that were euthanized were individually observed for overt pathology by necropsy, and the 50% lethal dose (LD50) was calculated by the Bliss method on day 14. The vital organs were removed, fixed, and preserved for pathological examination, and the tissue samples were stained with hematoxylin and eosin (H&E). The histopathological changes were observed under a light microscope. The data on the number of animals, the survival ratio, and the mean survival time were analyzed using the Kaplan-Meier method. The differences between the groups were compared using the log-rank test. The p-values less than 0.05 were considered statistically significant.
and embedded in paraffin for histopathological analyses [38, 39].

Xenograft tumor model

All animal experiments complied with Southern Medical University's Policy on the Care and Use of Laboratory Animals. Five-week-old athymic BALB/c nu/nu male mice were used for in vivo experiments. The animals were housed at a constant room temperature with a 12 h light/12 h dark cycle and fed a standard rodent diet and water. H460 cells were harvested and injected subcutaneously (5 × 10^6 cells in 100 μl of phosphate-buffered saline (PBS)) into the mice. Treatment began after the size of the H460 tumors reached 50 mm^3, and the treatments consisted of intraperitoneal (i.p.) injections of DMSO, EE02 (5 mg/kg b.w. in 100 μl of DMSO), EE02 (10 mg/kg b.w. in 100 μl of DMSO) or erlotinib (10 mg/kg b.w. in 100 μl of DMSO). The treatment was performed every 2 days. Tumor growth was monitored by a digital caliper, and the maximum tumor volume was not allowed to exceed 1500 mm^3. At the end of the experiment, the animals were sacrificed, and the tumors were removed. The tumor volumes were determined by measuring the tumor length (L) and width (W) and calculating the volume (V = 0.5 × L × W^2), [40]. Tumor samples were excised, fixed, and embedded in paraffin for immunohistochemical (IHC) analyses [41, 42].

Statistical analysis

Statistical significance was evaluated using SPSS 21.0 software. P < 0.05 was considered statistically significant. * Represents P < 0.05, ** represents P < 0.01, and *** represents P < 0.001.

Results

Discovery of EE02 through structure-based virtual database screening

The EGFR binding region of EPS8 is predicted to target the JXM domain of EGFR. We hypothesized that a small molecule that binds to the JXM domain of EGFR will compete with EPS8, consequently blocking the EGFR/EPS8 interaction. With the aid of structure-based virtual screening, we chose a crystal structure of EGFR (PDB ID code 3GOP) that includes the kinase region and the JXM domain. Using SYBYL software to predict and generate the docking pocket of EGFR (Fig. 1a), we narrowed
our interest from a total of 390,000 compounds to 50 top candidate compounds and were able to obtain chemical samples of 29 of the top 50 compounds. We first tested the effects of these 29 molecules on the proliferation of A549 and BT549 cell lines by using CCK-8 assays in vitro. Of the 29 compounds tested, the most promising compound was EE02 (ChemDiv No. 0884–0022), which was obtained from TopScience Co., Ltd. (Fig. 1e and f). EE02 is a synthetic compound with a molecular weight of 767 (Fig. 1d). The model of EE02 binding to EGFR was generated by SYBYL software and refined by structural organization using PyMOL software. The refined model, shown in Fig. 1b and c, predicted that EE02 binds the JXM domain and the meshed area where the JXM domain intersects with the kinase domain and forms a number of hydrogen bonds with nearby residues, including Ser-671 and Arg-807 (Fig. 1c).

EE02 significantly inhibited the viability and proliferation of EGFR-positive and Eps8-positive breast cancer and NSCLC cells

Initially, to screen the expression levels of EGFR and EPS8 in cancer and normal cell lines, we performed a western blot analysis. The results indicated EGFR overexpression in the MDA-MB-468, H460, A549 and BT549 cell lines; moderate EGFR expression in the H1975 cell line; and very low EGFR expression in the MCF-7, IM-9, MCF-10A and BEAS-2B cell lines. EPS8 was overexpressed in all six breast cancer and NSCLC cell lines (MDA-MB-468, H460, A549, H1975, MCF-7 and BT549), moderate expressed in normal cell lines (MCF-10A and BEAS-2B) and very low expressed in IM-9 cell line (Fig. 2a). Then, to assess the activity of EE02, A549, H460, H1975, BT549, MDA-MB-468 and MCF-7 cells were treated for 24 h with increasing concentrations of the inhibitor EE02 (0–10 μM). The dose-dependent antiproliferative effect of EE02 was determined...
using CCK-8 assays (Fig. 2c). However, at a 10 μM concentration, the antiproliferative effect of the inhibitor EE02 on the proliferation of the A549, H460, H1975, BT549 and MDA-MB-468 cancer cells was significantly stronger than that on the proliferation of the MCF-7 cells, which overexpress EP8 but not EGFR \( (P = 0.003, 0.008, 0.008, 0.008 \text{ and } 0.009, \text{ respectively, t-tests}) \) (Fig. 2a and c). We then examined the effect of EE02 on the colony formation capability of the breast carcinoma and NSCLC cells and found that the inhibitor EE02 significantly reduced colony numbers of A549 \( (P < 0.001, \text{ one-way ANOVA}) \), H460 \( (P < 0.001, \text{ one-way ANOVA}) \), H1975 \( (P < 0.001, \text{ one-way ANOVA}) \) and BT549 \( (P < 0.001, \text{ one-way ANOVA}) \) in a dose-dependent manner (Fig. 2b). At 5 μM, the inhibitory effect of EE02 on the colony formation capability of the A549 and H460 cancer cells was stronger than that on the colony formation capability of the MCF-7 cells (Fig. 2b). Moreover, EE02 did not result in significant suppression in normal cell lines (MCF-10A and BEAS-2B, less than 40% suppression) and peripheral blood mononuclear cells (PBMCs) from 5 untreated healthy volunteers (less than 30% suppression), suggesting that EE02 possesses specificity toward cancer cells that overexpress EGFR and EP8 (Fig. 2a and e).

**EE02 promotes apoptotic cell death**

To examine the apoptotic effect of EE02, A549, H460, MDA-MB-468 and MCF-7 cells were treated with DMSO or EE02 for 24 h and then stained with annexin V and propidium iodide (PI). As is shown in Fig. 3a, after 24 h of exposure to 10 μM EE02, a significant increase in the apoptosis rates of A549 \( (P = 0.005, \text{ t-test}) \), H460 \( (P = 0.026, \text{ t-test}) \), MDA-MB-468 \( (P = 0.003, \text{ t-test}) \) and MCF-7 \( (P = 0.004, \text{ t-test}) \) cell lines were observed (Fig. 3a). The ability of EE02 to promote apoptosis was significantly stronger in the A549, H460 and MDA-MB-468 cancer cells than in the MCF-7 cells \( (P = 0.037, 0.045 \text{ and } 0.016, \text{ respectively, t-test}) \) (Fig. 3a).

![Fig. 3](image-url)  
**Fig. 3** Effect of EE02 on apoptosis of cells in vitro. **a** Cancer cells were incubated with DMSO or EE02 (10 μM) for 24 h and then analyzed for apoptosis using annexin V/PI staining assays. The quantification of the annexin V/PI staining is shown. **b** PBMCs from 5 untreated healthy donors were incubated with DMSO or EE02 (10 μM) for 24 h and then analyzed for apoptosis using annexin V/PI staining assays. The quantification of the annexin V/PI staining is shown. **c** Normal cell lines were incubated with DMSO or EE02 (10 μM) for 24 h and then analyzed for apoptosis using annexin V/PI staining assays. The quantification of the annexin V/PI staining is shown.
Moreover, EE02 did not result in a significant promotion of apoptosis in normal cell lines (MCF-10A and BEAS-2B, less than 7% apoptotic cells) and PBMCs from 5 untreated healthy volunteers (less than 5% apoptotic cells), suggesting that EE02 possesses specificity toward cancer cells that overexpress EGFR and EPS8 (Fig. 3b and c).

**EGFR knockdown reduces the sensitivity of cancer cells to EE02**

To verify that the antitumor effect of EE02 on cancer cells was related to the EGFR protein, we knocked down EGFR expression in H460, A549 and MDA-MB-468 cells; performed western blotting and gray values analysis; and compared the results with those of the vehicle-treated H460, A549 and MDA-MB-468 cells. As shown in Fig. 4b, the EGFR expression in the H460-EGFR/shRNA1 and H460-EGFR/shRNA2 cells was significantly downregulated compared to that in the H460-NC cells, and the same was true of the A549 and MDA-MB-468 cell lines. Subsequently, to detect whether the sensitivity of tumor cells to EE02 was reduced after knocking down EGFR, the cancer cells were treated for 24, 48 or 72 h with increasing concentrations of the inhibitor EE02 (H460: 0–3.0 μM; A549: 0–5.0 μM; and MDA-MB-468: 0–2.5 μM), and CCK-8 assays were then performed. The results showed that the sensitivity of the A549, H460 and MDA-MB-468 cells to the inhibitor EE02 was significantly decreased after the knockdown of EGFR expression, suggesting that the antitumor effect of EE02 is related to EGFR (Fig. 4d).

**EGFR overexpression increases the sensitivity of cancer cells to EE02**

To verify that the inhibitor EE02 acts as an antitumor agent by targeting the EGFR JXM domain, we designed a mutant receptor, mut-EGFR, in which the JXM domain is replaced by a (GGS)10 sequence (Fig. 4a). The
sequence has been demonstrated to lack a regular secondary structure and to be very flexible. The plasmid was created as described in the Methods. Briefly, amino acids 650–679 of EGFR were replaced by the (GGS)$_{10}$ sequence.

MCF-7 cells were transfected with wt-EGFR, mut-EGFR, or the empty vector. The transfected cells were analyzed by western blotting and gray values analysis, and the results were compared with those of the vehicle-treated MCF-7 cells. As shown in Fig. 4b, the EGFR expression levels in the MCF-7-wt-EGFR and MCF-7-mut-EGFR cells were significantly upregulated compared to those in the MCF-7-NC cells. Subsequently, to detect whether the sensitivity of tumor cells to EE02 increased after the overexpression of EGFR, the cancer cells were treated for 24 h, 48 h or 72 h with increasing concentrations of the inhibitor EE02 (0–5.0 μM), and then CCK-8 assays were performed. The results showed that the sensitivity of the MCF-7-wt-EGFR cells to the inhibitor EE02 was significantly higher than that of the other transfected cells, but there was no significant difference between the sensitivities of the MCF-7-mut-EGFR and MCF-7-NC cells. The results indicate that the antitumor effect of EE02 is mediated by targeting the EGFR JXM domain (Fig. 4d).

**EE02 blocks the EGFR/EPS8 interaction and suppresses EPS8 downstream signaling in cancer cells**

Previous results have shown that EE02 inhibits the proliferation of tumor cells by targeting the JXM domain of EGFR. EGFR is a transmembrane protein, and EPS8 is an intracellular protein. We assume that Eps8 interacts with the JXM domain of EGFR, which is intracellular and close to the membrane. The communoprecipitation results showed that in A549, H460 and MDA-MB-468 cells, which express both EGFR and EPS8, Eps8 interacted with EGFR to form an EGFR/EPS8 complex (Fig. 4c). Can the inhibitor EE02 disrupt the EGFR/EPS8 interaction by binding to the JXM domain of EGFR? To test this hypothesis, MDA-MB-468 cells expressing high levels of endogenous EGFR and EPS8 were treated with EE02 (10 μM) for 24 h. Coimmunoprecipitation was performed using an anti-EGFR antibody. The results indicated that the treatment with EE02 resulted in EGFR/EPS8 complex dissociation. As is shown in Fig. 4c, little EPS8 was detected in the EGFR immunoprecipitants after the treatment with the inhibitor EE02. Our results showed that EE02 is a potent inhibitor that was predicted to bind to the EGFR JXM domain and block the EGFR/EPS8 complex.

EE02 blocks EGFR/EPS8 complex formation by competitively binding to the JXM domain of EGFR. What effects does EE02 have on the signaling pathway downstream of this complex? To further examine the inhibitory effect of EE02 on EGFR/EPS8 complex downstream signaling, we detected the expression of EGFR/EPS8 complex target proteins by protein chip assays. MDA-MB-468 is a breast cancer cell line that expresses high levels of EGFR and Eps8. We examined protein levels after these cells were treated with EE02 (10 μM) for 24 h. We also included a control group treated with DMSO. The protein chip results showed that the levels of p-Akt, p-4E-BP-1, p-Erk1/2, p-Gsk3β, p-mTOR, p-p70S6K, p-PRAS40 and p-RPS6 were apparently decreased after the treatment with EE02 compared with that after the treatment with DMSO, but there was no difference between the EE02 group and the DMSO control group in the expression of other proteins on these protein chips (Fig. 5a).

To further identify the inhibitory effect of EE02 on downstream MAPK/Erk and PI3K/Akt signaling, we measured EGFR, Eps8, Akt, p-Akt, Erk and p-Erk protein expression in MDA-MB-468 and H460 (NSCLC cell line) cells after EE02 treatment for 24 h. The Akt, p-Akt, Erk and p-Erk protein levels were inhibited in a dose-dependent manner in these two cell lines, while the total EGFR and Eps8 protein levels were unaffected (Fig. 5b and c).

**Acute intraperitoneal toxicity study**

The results of the intraperitoneal single-dose toxicity study are summarized in Table 1. No mice died after receiving an intraperitoneal dose of up to 75.00 mg/kg b.w. EE02. Conversely, both female and male mice died when given an intraperitoneal dose of 150.85 mg/kg b.w. EE02. In other groups, different numbers of mice died, and as the dose increased, the number of mice that died gradually increased (Table 1). According to these results, the approximate LD$_{50}$ in the mice was determined to be 101.92 mg/kg b.w. by the Bliss method, and the 95% confidence interval was 93.67 mg/kg b.w. to 110.49 mg/kg b.w.. No adverse effects or clinical signs of toxicity were observed in the surviving mice during the study except for slight weight loss during the first week after the EE02 treatment. However, in the second week, the mice gradually gained weight and approached their pretreatment weights (Fig. 6a, b and c).

In addition to lethality, other parameters should be considered and investigated in acute toxicity studies to identify signs of toxicity or toxic potential in specific organs. Therefore, macroscopic and histological analyses were performed in the liver, spleen and kidneys. In addition, the testes of the male mice were also examined. Macroscopic analysis showed no changes in the color or morphology of the liver, spleen, kidneys or testes when the mice were treated intraperitoneally with the different doses of the inhibitor EE02 or DMSO. Further histological analysis showed no gross pathological findings and no significant differences in the liver, spleen, kidneys or testes between the EE02- and DMSO-treated mice (Fig. 6d and e).
Fig. 5 The inhibitory effects of EE02 on EGFR/Eps8 complex-associated signaling. a The results of protein chip assays are shown. MDA-MB-468 cells were incubated with DMSO or EE02 (10 μM) for 24 h, and then total protein was extracted for protein chip assays. b Western blot assays for the expression of EGFR, EPS8, Akt, p-Akt, Erk and p-Erk were performed with MDA-MB-468 cells treated with increasing concentrations of EE02 for 24 h. c Western blot assays for the expression of EGFR, EPS8, Akt, p-Akt, Erk and p-Erk were performed with H460 cells treated with increasing concentrations of EE02 for 24 h.

Table 1 Intraperitoneal inject single-dose toxicity of EE02 in mice

| Group                  | n | Dose (mg/kg b.w.) | Logarithmic Dose | Mortality | Mortality Rate (%) |
|------------------------|---|-------------------|------------------|-----------|--------------------|
| Vehicle control group  | 10| 5 (mL/kg b.w.)    | 0                | 0/10      | 0                  |
| 1                      | 10| 75.00             | 1.875            | 0/10      | 0                  |
| 2                      | 10| 86.25             | 1.936            | 3/10      | 30                 |
| 3                      | 10| 99.19             | 1.996            | 4/10      | 40                 |
| 4                      | 10| 114.07            | 2.057            | 7/10      | 70                 |
| 5                      | 10| 131.18            | 2.118            | 9/10      | 90                 |
| 6                      | 10| 150.85            | 2.179            | 10/10     | 100                |
The acute toxicity study for EE02 was conducted in mice to establish the potential for acute toxicity and to provide information pertaining to the upper dose limit for longer-term feeding studies. On the basis of the toxicity study results, the estimated LD_{50} of EE02 in mice is 101.92 mg/kg b.w. Under the conditions of this study, a unique composition of EE02 and DMSO did not produce any acute intraperitoneal toxicological effects. This indicates that EE02 has relatively low toxicity and high potential for development as a new drug.

Efficacy of EE02 in an animal model
We next sought to explore whether EE02 exhibited anticancer activity in an orthotopic H460 xenograft mouse model. Compared to the DMSO treatments, the low-dose EE02 (5 mg/kg b.w., \( P = 0.003, \) t-test), high-dose EE02 (10 mg/kg b.w., \( P < 0.001, \) t-test) and erlotinib (10 mg/kg b.w., \( P < 0.001, \) t-test) treatments significantly suppressed tumor growth, as is shown by the photos of the tumors excised at the end of the experiment (Fig. 7e). Compared with low-dose EE02 (5 mg/kg b.w., \( P = 0.003, \) t-test) and erlotinib (10 mg/kg b.w., \( P < 0.001, \) t-test) significantly inhibited tumor growth in the H460 xenograft model (Fig. 7b and d). There was no difference between the high-dose EE02 (10 mg/kg b.w.) and erlotinib (10 mg/kg b.w.) treatments (\( P = 0.236, \) t-test) (Fig. 7b and d). We monitored mouse body weights over a 20-day period to assess toxicity and found no statistically significant differences in mouse body weight among the four experimental groups, indicating that these inhibitors have very low or no toxicity in vivo (Fig. 7c). As is shown in Fig. 7f, compared to those from the DMSO control mice, the tumors from the EE02-treated mice showed decreased proliferation, as assessed by Akt, Erk, p-Akt, p-Erk and ki-67 staining. These data demonstrated that EE02 is a potential inhibitor that is able to reduce the growth of tumors.
Discussion

The JXM domain of EGFR is a critical region for EGFR activation and the binding site Eps8 uses to form the EGFR/Eps8 complex [13–17, 27, 43]. According to XiaolingXie et al., peptide 327 derived from the Eps8 can bind to the EGFR JXM domain and effectively reduce EGFR/Eps8 complex, which thereby affects EGFR signaling and reduces cell viability [2]. Effective though, peptide inhibitors have the disadvantages of being difficulty in penetrating the membrane and the usage of high drug dosage [2, 44–46]. Quite on the contrary, using drug-like, nonpeptide small molecules to disrupt the EGFR/Eps8 complex conformation may have several advantages, including improved cell permeability, small dosage, better in vivo stability and bioavailability [30], which are more in line with clinical application requirements. In this study, we used a computational screening approach to identify potential small-molecule inhibitors of the EGFR/Eps8 complex from a database of 390,000 small molecules. Of the 29 candidate compounds tested, EE02 showed remarkable inhibition of the growth of tumor cells with high expression of EGFR and Eps8 and promoted apoptosis, while did not
significantly inhibit and promote apoptosis in normal cell lines (Fig. 1, Fig. 2 and Fig. 3).

Next, we proposed that the observed antitumor effects of the inhibitor EE02 could be explained by competitive protein binding between EE02 and Eps8 towards EGFR. The JXM domain of EGFR is critical for receptor activation [13–17], and targeting this region could be a promising strategy. To further confirm whether the inhibitor EE02 directly binds to the JXM domain of EGFR and disrupts the EGFR/Eps8 complex conformation, we designed a mut-EGFR in which the JXM domain of EGFR was replaced by a 30 amino acid (GGS)10 linker. Such mut-EGFR is very similar to and of the same length as wt-EGFR (Fig. 4a). This substitution did not affect the structure or function of the transmembrane and kinase domains. Results showed that the inhibitory effect of EE02 on the proliferation of the MCF-7 cells overexpressing wt-EGFR was significant, but there was no significant change in the proliferation of the MCF-7 cells overexpressing mut-EGFR compared with that of the MCF-7-NC cells (Fig. 4d). Such results indicate that the inhibitor EE02 directly binds to the JXM domain of EGFR and competitively blocks the formation of the EGFR/Eps8 complex.

We further hypothesized that the EGFR/Eps8 complex inhibitor could negatively affect the survival of cancer cells by suppressing the downstream signaling of EGFR/Eps8. Inhibitors that can block downstream or upstream elements in the EGFR signaling pathway have been extensively studied in cancer research over the past two decades with the reasons that EGFR downstream signaling regulates tumor progression via proliferation, angiogenesis, metastasis and drug resistance mechanisms [2, 8, 47–50].

In our study, western blotting and protein chip assays both showed that the inhibitor EE02 could downregulate the expression of Akt, p-Akt, Erk and p-Erk (Fig. 5), which firmly support our hypothesis. Our results were compatible with those of a previous study, which demonstrated that the activation of the PI3K/Akt/mTOR and MAPK/Erk pathways could promote cancer cell proliferation.

Small-molecule EGFR inhibitors, such as erlotinib and gefitinib, compete reversibly with ATP to bind to the kinase domain of EGFR and, thus, inhibit EGFR autophosphorylation and downstream signaling [48, 51, 52]. However, the structure of the kinase domain of EGFR is very unstable and can be easily mutated, which may cause problems such as drug resistance of small molecule inhibitors targeting this region [8, 53–59], thereby limiting their clinical application. Compared with the kinase domain, the JXM domain of EGFR is relatively conserved with more stable structure and is not easy to mutate [14]. This may mean that small molecule inhibitors targeting this region are not prone to drug resistance and have a better application prospect. The vivo studies provided primary evidence that the inhibitor EE02 could selectively inhibit H460 cancer cell growth in the xenograft nude mouse model. What’s more, there showed no significant difference in the antitumor effects between erlotinib and EE02 at the same dose (Fig. 7), implying that EE02 may be a novel antitumor drug.

Conclusions

In summary, using a combination of virtual screening and biochemical assays, we have screened small molecules and demonstrated that the inhibitor EE02, a specific EGFR/Eps8 inhibitor, can bind to the JXM domain of EGFR and directly inhibit the EGFR interaction with Eps8. The present study is the first successful attempt to identify direct disruptors of the EGFR/Eps8 complex using an in silico virtual screening approach, and this approach resulted in the identification of the inhibitor EE02. On the basis of these results, more potent EGFR/Eps8 complex inhibitors should be investigated, with the goal of developing novel therapeutic strategies that can act as complementary approaches to treat EGFR-positive and Eps8-positive malignancies.

Abbreviations

- aa: Amino acids; CoIP: Coimmunoprecipitation; EGFR: Epidermal growth factor receptor; Eps8: Epidermal growth factor receptor phosphate substrate 8; ICD: Intracellular domain; IHC: Immunohistochemical; JXM: Juxtamembrane; NSCLC: Non-small cell lung cancers; PBS: Phosphate-buffered saline; PDB: Protein data bank; PI: Propidium iodide; PTB: Phosphotyrosine binding protein; RNAi: RNA interference; RTK: Receptor tyrosine kinase; SAM-PNT: Sterile alpha-pointed; SPF: Specific pathogen-free

Acknowledgements

The authors are grateful to Jingwen Du (Department of hematology, Zhujiang Hospital, Guangzhou, China) for providing flow cytometry assistance.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81372249]; the Science and Technology Planning Project of Guangdong Province, China [grant number 2016A020213005 and 2017A020215043]; the Science and Technology Planning Project of Guangzhou [grant number 201704020216]; the Clinical Research Project of Southern Medical University [grant number LC2016ZD027]; the Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZRR1010504].

Availability of data and materials

Materials is available upon request.

Authors’ contributions

YHL and MFL participated in the design of the study, MFL, JLY and LHZ performed the experiments and wrote the paper. SFT and XZ collected and analyzed the data. YJH, ZT and WJZ provide assistance with revising the manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

The study was approved by the ethical review board of Zhujiang Hospital (Guangzhou, China).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Hematology, Zhuijiang Hospital, Southern Medical University, No. 253 GongyeDadaoZhong, Guangzhou, Guangdong 510282, People's Republic of China. 2State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, People's Republic of China.

Received: 2 December 2018 Accepted: 2 May 2019

References
1. Peela N, Truong D, Saini H, Chu H, Mashaghi S, Ham SL, et al. Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis. BIOMATERIALS. 2017;133:176–207.
2. Xie X, Zhou W, Hu Y, Chen Y, Zhang H, Li Y. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. CELL DEATH DIS. 2018;9(3).
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 2002-01-10;346(2):92–98.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016(46):1–29.
5. Chollet T, Bost K, Alvarado D, Marovic J, Draganovic M, Komlodi E, et al. A novel anti-cancer therapy based on the EGF receptor juxtamembrane domain. J BIOL CHEM. 2014;289(20):35485–50.
6. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. CELL. 2002;109(6):669–72.
7. Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol (Camb). 2011;3(1):17–30.
8. Roskoski R. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res. 2014;87:42–59.
9. Hubbard SR. The Juxtamembrane Region of EGFR Takes Center Stage. CELL. 2009;137(7):1181–3.
10. Cardillo E, Tortora G. EGFGR antagonists in cancer treatment. N Engl J Med. 2002;346(13):1160–74.
11. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. CELL. 2002;109(6):669–72.
12. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular and evolutionary perspectives. EXP CELL RES. 2005;302(1):108–15.
13. McCracken M, Olsen M, Chen MJ, Jemal A, Thun M, Cokkinides V, et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA. Cancer J Clin. 2007;57(4):190–205.
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA. Cancer J Clin. 2006;56(2):106–30.
15. Tietz T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol (Camb). 2011;3(1):17–30.
16. Roskoski R. ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors. Pharmacol Res. 2014;87:42–59.
17. Hubbard SR. The Juxtamembrane Region of EGF R Takes Center Stage. CELL. 2009;137(7):1181–3.
18. Cardillo E, Tortora G. EGFGR antagonists in cancer treatment. N Engl J Med. 2002;346(13):1160–74.
19. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. CELL. 2002;109(6):669–72.
20. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular and evolutionary perspectives. EXP CELL RES. 2005;302(1):108–15.
21. Red Brewer M, Choi SH, Alvarado D, Mosarcvic K, Pozzi A, Lumen MA, et al. The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain. MOL CELL. 2009;34(6):641–51.
22. Boran ADW. The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor. BIOCHEM SOC T. 2012;40(1):195–9.
23. Thiel KW, Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proceedings of the National Academy of Sciences. 2007.104(49):19238.
24. Jura N, Endres NF, Engel K, Deindl S, Das R, Lammers MH, et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. CELL. 2009;137(7):293–307.
25. Choowongkomon K, Carlin CR, Sonnichsen FD. A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor. J BIOL CHEM. 2005;280(23):24043–52.
26. Aifa S, Aydin J, Nordvall G, Lundstrom S, Svensson SP, Hermanson O. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. EXP CELL RES. 2005;302(1):108–14.
27. Sinclair JKL, Schepartz A. Influence of Macrocytization on Allosteric Juxtamembrane-Derived, Stapled Peptide Inhibitors of the Epidermal Growth Factor Receptor (EGFR). ORG LETT. 2014;16(16):4916–9.
28. Pascoli F, Minichelli L, Matoska V, Castagnino P, Miki T, Wong WT, et al. Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. The EMBO Journal. 1993;12(10):3799–808.
29. Di Fiore PP, Scita G. Epis in the midst of GTPases. Int J Biochem Cell Biol. 2002;34(10):1178–83.
46. Rizzuti M, Nizzardo M, Zanetta C, Ramirez A, Corti S. Therapeutic applications of the cell-penetrating HIV-1 tat peptide. Drug Discov Today. 2015 Jan;20(1):76–85.

47. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):213–22.

48. Lurje G, Lenz H. EGFR signaling and drug discovery. Oncology. 2009;77(6):400–10.

49. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. The New England Journal of Medicine. 2010;362(25):2380–8.

50. Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J CLIN ONCOL. 2013;31(27):3327–34.

51. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007;67(14):2045–75.

52. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(Suppl 4):40–8.

53. Song H, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non–small cell lung cancer. J Thorac Oncol. 2016;11(4):e45–7.

54. Yu HA, Tian SK, Dilton AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. JAMA ONCOL. 2015;1(7):982–4.

55. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Koehler O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786–92.

56. Mok TS, Wu Y, Thongprasert S, Yang J, Yang C, Chu D, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine. 2009;361(10):947–57.

57. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible Inhibitors of the EGF Receptor May Circumvent Acquired Resistance to Gefitinib. P NATL ACAD SCI USA. 2005;102(21):7665–70.

58. Wu S, Shih J. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. MOL CANCER. 2018(171).

59. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. CLIN CANCER RES. 2015;21(17):3924–33.